Cancer Genetics, Inc. Announces Exercise of Underwriters' Over-Allotment Option
Published: Sep 05, 2013
RUTHERFORD, N.J., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the diagnosis and prediction of treatment outcomes for difficult to diagnose cancers, today announced a partial exercise of the over-allotment option granted to the underwriters to purchase an additional 105,000 shares of common stock at a price of $10.00 per share, bringing the total gross proceeds from the offering to $16,050,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
Help employers find you! Check out all the jobs and post your resume.